Literature DB >> 26761275

Implementation and Operational Research: Implementation of the WHO 2011 Recommendations for Isoniazid Preventive Therapy (IPT) in Children Living With HIV/AIDS: A Ugandan Experience.

Paola Costenaro1, William Massavon, Rebecca Lundin, Sandra M Nabachwa, Federica Fregonese, Erika Morelli, Agnes Alowo, Maria Nannyonga Musoke, Charles P Namisi, Susan Kizito, Davide Bilardi, Antonio Mazza, Mark F Cotton, Carlo Giaquinto, Martina Penazzato.   

Abstract

BACKGROUND: Intensified tuberculosis (TB) case finding and isoniazid preventive therapy (IPT) are strongly recommended for children who are HIV infected. Data are needed to assess the feasibility of the WHO 2011 intensified tuberculosis case finding/IPT clinical algorithm.
METHODS: Children who are HIV infected and attending Nsambya Home Care at Nsambya Hospital, Uganda, were screened for TB following WHO recommendations. IPT was given for 6 months after excluding TB. Factors associated with time to IPT initiation were investigated by multivariate Cox proportional hazard regression. Health care workers were interviewed on reasons for delay in IPT initiation.
RESULTS: Among the 899 (49% male) children with HIV, 529 (58.8%) were screened for TB from January 2011 to February 2013. Children with active TB were 36/529 (6.8%), 24 (4.5%) were lost to follow-ups and 280 (52.9%) started IPT, 86/280 (30.7%) within 3 months of TB screening and 194/280 (69.3%) thereafter. Among the 529 children screened for TB, longer time to IPT initiation was independently associated with cough at TB screening (hazard ratio 0.62, P = 0.02, 95% confidence interval: 0.41 to 0.94). Four children (1% of those starting treatments) interrupted IPT because of a 5-fold increase in liver function measurements. In the survey, Health care workers reported poor adherence to antiretroviral therapy, poor attendance to periodic HIV follow-ups, and pill burden as the 3 main reasons to delay IPT.
CONCLUSION: In resource-constrained settings, considerable delays in IPT initiation may occur, particularly in children with HIV who are presenting with cough at TB screening. The good safety profile of isoniazid in antiretroviral-therapy-experienced children provides further support to IPT implementation in this population.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26761275     DOI: 10.1097/QAI.0000000000000806

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  4 in total

1.  Integrated TB and HIV care for Mozambican children: temporal trends, site-level determinants of performance, and recommendations for improved TB preventive treatment.

Authors:  W Chris Buck; Hanh Nguyen; Mariana Siapka; Lopa Basu; Jessica Greenberg Cowan; Maria Inês De Deus; Megan Gleason; Ferreira Ferreira; Carla Xavier; Benedita Jose; Criménia Muthemba; Beatriz Simione; Peter Kerndt
Journal:  AIDS Res Ther       Date:  2021-01-09       Impact factor: 2.250

2.  Drop-offs in the isoniazid preventive therapy cascade among children living with HIV in western Kenya, 2015-2019.

Authors:  Dickens Otieno Onyango; Marianne A B van der Sande; Courtney M Yuen; Jerphason Mecha; Daniel Matemo; Elizabeth Oele; John Kinuthia; Grace John-Stewart; Sylvia M LaCourse
Journal:  J Int AIDS Soc       Date:  2022-08       Impact factor: 6.707

3.  Uptake of Isoniazid Preventive Therapy among Under-Five Children: TB Contact Investigation as an Entry Point.

Authors:  Yared Tadesse; Nigussie Gebre; Shallo Daba; Zewdu Gashu; Dereje Habte; Nebiyu Hiruy; Solomon Negash; Kassahun Melkieneh; Degu Jerene; Yared K Haile; Yewulsew Kassie; Muluken Melese; Pedro G Suarez
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

4.  Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania.

Authors:  Olivia F Hunter; Furaha Kyesi; Amrit Kaur Ahluwalia; Zeinabou Niamé Daffé; Patricia Munseri; C Fordham von Reyn; Lisa V Adams
Journal:  BMC Infect Dis       Date:  2020-10-07       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.